By Mariam Sunny (Reuters) -Biohaven said on Monday its experimental treatment for a rare neuromuscular disorder failed to significantly improve motor function in a late-stage trial, sending the shares ...

As the ski season kicks off, new research from UBC is shedding light on the number of spinal cord injuries that British ...

The plaintiff's attorney said the biggest hurdle in the case had to do with proving causation, since the plaintiff had ...

Despite disappointing results in the genetic neurodegenerative disorder, the drug shows potential for treating obesity.

A new study emphasizes that neighborhood conditions significantly shape recovery opportunities for individuals with SCI and advocates for environmental interventions to reduce health inequities.

Scientists at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have uncovered an ...

The New Haven, Conn., biopharmaceutical company said Monday that taldefgrobep had shown clinically meaningful improvements in motor function in spinal muscular atrophy patients, but the treatment arm ...

Biohaven's Phase 3 trial of taldefgrobep alfa failed to meet its primary endpoint in spinal muscular atrophy, causing a 10% ...

In a breakthrough towards redefining pain management, a team of spine surgeons and pain specialists at Apollo Cancer Centre ...

Spinal cord stimulation (SCS) for treatment of chronic pain in the back and/or lower extremities is associated with greater ...

OVER 2,000 people participated in a charity fun run themed “Together We Care” aimed at raising awareness and support for individuals affected by spinal muscular atrophy (SMA).

The protein netrin1 has an entirely unanticipated role in organizing the spinal cord during early development.